Brief: Nuvectis Pharma Announces Preclinical Data For NXP800
13/09/2022 13:41
Sept 13 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA ANNOUNCES POSITIVE DATA FOR NXP800 IN A
PRECLINICAL MODEL OF ARID1A-MUTATED GASTRIC CARCINOMA
* NUVECTIS PHARMA INC - NXP800 PHASE 1A DOSE ESCALATION
STUDY IS
PROGRESSING AS PLANNED, EXPECTS TO BEGIN PHASE 1B PORTION OF
STUDY IN Q1 2023
Source text for Eikon: ID:nGNXbFCZgJ
Further company coverage: NVCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin